These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23279299)

  • 1. Infections following facial composite tissue allotransplantation--single center experience and review of the literature.
    Knoll BM; Hammond SP; Koo S; Issa NC; Tullius SG; Baden LR; Pomahac B; Marty FM
    Am J Transplant; 2013 Mar; 13(3):770-9. PubMed ID: 23279299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
    Korneffel K; Mitro G; Buschor K; Rees M; Ortiz J
    Transpl Immunol; 2019 Oct; 56():101226. PubMed ID: 31344441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.
    Santos CA; Brennan DC; Saeed MJ; Fraser VJ; Olsen MA
    Clin Transplant; 2016 Apr; 30(4):435-44. PubMed ID: 26841129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
    Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P
    Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.
    Cristelli MP; Felipe CR; Prizmic PSS; de Azevedo VFD; Viana LA; Tavares MG; Wagner de Castro Lima Santos D; de Paula MI; Medina-Pestana JO; Tedesco-Silva Junior H
    Clin Transplant; 2019 Oct; 33(10):e13689. PubMed ID: 31400155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis.
    Beam E; Lesnick T; Kremers W; Kennedy CC; Razonable RR
    Clin Transplant; 2016 Mar; 30(3):270-8. PubMed ID: 26701733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression.
    Shah AP; Chen JM; Fridell JA
    Clin Transplant; 2015 Dec; 29(12):1221-9. PubMed ID: 26458498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
    Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.
    Kruger RM; Paranjothi S; Storch GA; Lynch JP; Trulock EP
    J Heart Lung Transplant; 2003 Jul; 22(7):754-63. PubMed ID: 12873543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.
    George MJ; Snydman DR; Werner BG; Griffith J; Falagas ME; Dougherty NN; Rubin RH
    Am J Med; 1997 Aug; 103(2):106-13. PubMed ID: 9274893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infectious complications in three double hand recipients: experience from a single center.
    Bonatti H; Brandacher G; Margreiter R; Schneeberger S
    Transplant Proc; 2009 Mar; 41(2):517-20. PubMed ID: 19328916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor.
    Vincenti F; Budde K; Merville P; Shihab F; Ram Peddi V; Shah M; Wyburn K; Cassuto-Viguier E; Weidemann A; Lee M; Flegel T; Erdman J; Wang X; Lademacher C
    Am J Transplant; 2018 Dec; 18(12):2945-2954. PubMed ID: 29745007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience.
    Sund F; Tufveson G; Döhler B; Opelz G; Eriksson BM
    Nephrol Dial Transplant; 2013 Mar; 28(3):758-65. PubMed ID: 23243043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
    Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study.
    Kauke-Navarro M; Panayi AC; Formica R; Marty F; Parikh N; Foroutanjazi S; Safi AF; Mardini S; Razonable RR; Morelon E; Gelb B; Rodriguez E; Lassus P; Pomahac B
    Transplantation; 2022 Oct; 106(10):2031-2043. PubMed ID: 35389381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed graft function and rejection are risk factors for cytomegalovirus breakthrough infection in kidney transplant recipients.
    Kleinherenbrink W; Baas M; Nakhsbandi G; Hesselink DA; Roodnat JI; de Winter BC; Hilbrands L; van Gelder T
    Pharmacol Res; 2021 May; 167():105565. PubMed ID: 33744428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.